Literature DB >> 7352423

Eosinophilia in systemic mastocytosis.

L T Yam, C F Yam, C Y Li.   

Abstract

The diagnosis of systemic mastocytosis depends on the proper recognition of extensive mast cells infiltration in tissues. Accurate identification of the mast cells in tissues may be difficult when there is no clinical suspicion to initiate a special search for these cells. Four patients with atypical clinical features and eosinophilia in tissues and three with eosinophilia in blood had hematologic or histologic findings suggestive of myelofibrosis with myeloid metaplasia, and malignant lymphoma. It was the presence of blood and tissue eosinophilia in these patients that led to further investigation and recognition of the diagnosis of systemic mastocytosis. Methods for identification of the mast cells are examined. The combined use of Wright-Giemsa stain, toluidine blue, and aminocaproate esterase is preferred. The eosinophils are intimately related to the mast cells. In cases of eosinophilia of unknown etiology, systemic mastocytosis should be considered one of the possible etiologic factors.

Entities:  

Mesh:

Year:  1980        PMID: 7352423     DOI: 10.1093/ajcp/73.1.48

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

Review 1.  Routine and specialised techniques in the diagnosis of haematological neoplasms.

Authors:  B J Bain
Journal:  J Clin Pathol       Date:  1995-06       Impact factor: 3.411

2.  Systemic mastocytosis: case report and literature review.

Authors:  A H Peterson
Journal:  J Natl Med Assoc       Date:  1984-05       Impact factor: 1.798

3.  Systemic mastocytosis, myelofibrosis and portal hypertension.

Authors:  A H Sawers; J Davson; J Braganza; C G Geary
Journal:  J Clin Pathol       Date:  1982-06       Impact factor: 3.411

Review 4.  Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Authors:  Ayalew Tefferi; Animesh Pardanani
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.